GPNMB has demonstrated significant expression in malignant tissues and has been recognized as a promising therapeutic target in various types of cancer, including epithelial ovarian cancer, hepatocellular cancer, colorectal cancer, breast cancer, and NSCLC 12-17. Here, GPNMB is linked to non-small cell lung carcinoma.